 BALTIMORE--BUSINESS WIRE--MyMD Pharmaceuticals, Inc. Nasdaq: MYMD MyMD or the Company, a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBDs superior potency over CBD by factor of 8,000 times. Supera-CBD is MyMDs pre-clinical patented synthetic cannabidiol CBD derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The study was conducted by Eurofins D 